Repurposing – second life for drugs

Porkodi Ayyar¹, Umamaheswari Subramanian²

¹ Assistant Professor of Pharmacology, SRM medical college hospital and research centre, SRM institute of science and technology, SRM nagar, Kattankulathur, Kanchipuram, India
² Assistant Professor of Pharmacology, Sri Venkateshwarra medical college hospital & research centre, Puducherry, India

Corresponding author: Porkodi Ayyar (porkodi.ayyar17@gmail.com)

Received 3 August 2021 ♦ Accepted 28 October 2021 ♦ Published 5 January 2022

Citation: Ayyar P, Subramanian U (2022) Repurposing – second life for drugs. Pharmacia 69(1): 51–59. https://doi.org/10.3897/pharmacia.69.e72548

Abstract

Drug repurposing refers to finding new indications for existing drugs. The paradigm shift from traditional drug discovery to drug repurposing is driven by the fact that new drug pipelines are getting dried up because of mounting Research & Development (R&D) costs, long timeline for new drug development, low success rate for new molecular entities, regulatory hurdles coupled with revenue loss from patent expiry and competition from generics. Anaemic drug pipelines along with increasing demand for newer effective, cheaper, safer drugs and unmet medical needs call for new strategies of drug discovery and, drug repurposing seems to be a promising avenue for such endeavours. Drug repurposing strategies have progressed over years from simple serendipitous observations to more complex computational methods in parallel with our ever-growing knowledge on drugs, diseases, protein targets and signalling pathways but still the knowledge is far from complete. Repurposed drugs too have to face many obstacles, although lesser than new drugs, before being successful.

Keywords

Indication switch, In silico method, Use patent, Re-profiling

Introduction

“The real voyage of discovery consists not in seeking new landscapes but in having new eyes”

Marcel Proust

In brief, drug repurposing refers to finding new indications for existing drugs which may be either approved and marketed or in clinical trials or shelved due to reasons other than safety. A repurposed drug may also include new dosage, new formulation, and new method of use or new patient population. Drug re-profiling, drug re-tasking, drug rescue, indication expansion or indication switching are other terms used for drug repurposing(Bellera et al. 2015). A new drug discovery begins with target identification for a disease of interest which may be an abnormal protein, a signalling pathway or a gene mutation related to the disease of concern. This is followed by high-throughput screening to identify 'hits' against the target. Those hits with maximum activity form the lead compounds which are then validated through assays and undergo optimisation to characterise the structure-activity relationship (SAR) and to enhance favourable pharmacokinetic properties of the compounds. Lead optimisation is then followed by preclinical and clinical studies(Zheng et al. 2013). Such a process is labour intensive, time consuming and too costly with no guarantee of success. In drug repurposing, the major difference from new drug discovery is that the lead compounds identified have established safety and large literature corpus which allows for accelerated drug development, reduced time consumption, lower cost and less risks (Fig. 1)(Bellera et al. 2015). Chlorpromazine, originally synthesized as an antimalarial...
was found to have sedative-anxiolytic effects in patients before surgery by a surgeon-anaesthesiologist in 1950 and later used successfully in acute mania as adjunct to barbiturates(Baker et al. 2018). These discoveries were made without knowing the precise mechanism underlying these effects. However, with the advent of advanced technologies, current repurposing strategies are evidence based demonstrating a degree of plausibility before the repurposed drugs enter clinical trials. In May 2012, the National Centre for Advancing Translational Sciences (NCATS), a component of National Institute of Health (NIH), launched “Discovery of New Therapeutic Uses for Existing Molecules” initiative to aid repurposing marketed drugs or new chemical entities in development and offer financial support(Gns et al. 2019).

Need for drug repurposing

From the medical community-patient perspective, drug repurposing has the ability to meet unmet medical needs- neglected diseases and, rare and orphan diseases(Bellera et al. 2015). It also has the potential to provide more effective treatment, cheaper alternative drugs, and drugs with favourable side effect profile in diseases where the available drugs have adverse side effect profile(Liu et al. 2013). It can also play a significant role in the development of personalised medicine(Naylor and Schonfeld 2014). New drug discovery faces the challenges of increasing Research & Development (R&D) costs, long timeline for drug development, low success rate and regulatory hurdles. In addition, pharmaceutical industry is also confronted with revenue loss from patent expiry and competition from generics and off-label prescription. Drug repurposing is claimed to be less costly, less time consuming, less risky and increased chance of success from the industrial perspective (Reaume 2011; R Flower 2013). The above-mentioned factors call for novel strategies for drug discovery and drug repurposing may provide an answer to the question.

Drug repurposing approaches

Drug repurposing strategies could be either drug oriented or disease oriented(Chen et al. 2015). In drug-oriented approach, repurposing efforts begin from the chemical or drug perspective. This method is preferred when extensive data regarding the drug is available. In disease-oriented approach, repurposing efforts begin with the symptoms, pathophysiology, or mechanism of disease. This method is preferred when a specific disease is under focus or if data on drug is inadequate. Successful drug repurposing more often incorporates both approaches(Dudley et al. 2011). Drug oriented repurposing could be either on-target or off-target repurposing (Fig. 2). In on-target repurposing, the known target of a drug is associated with diseases different from the drug’s original indication (example – sildenafil originally developed for angina repurposed for erectile dysfunction – molecular target in both is phosphodiesterase-5). Off-target repurposing is based on drug promiscuity or more aptly polypharmacology i.e., a drug can act on multiple targets and the secondary targets can be used for a new indication (example- cimetidine, a peptic ulcer drug repurposed for lung cancer). While off-target repurposing is significantly cost and labour intensive than on-target strategy, it is more innovative than the latter(Mucke 2010; Jin et al. 2012; Tari et al. 2012).

Methods of drug repurposing

Drug repurposing methods can be broadly classified into either activity based or in silico methods. Activity based methods include in vivo (living organisms) and in vitro high-throughput screening methods where the drug/chemical of interest is used for screening(Pihan et al. 2012; Shim and Liu 2014). In in-silico or computational or virtual screening methods, hits are identified in a systematic way from information gathered from various databases and involve tools to identify drug-target interactions. Activity based methods, though time and labour intensive in contrast to computational methods, are characterised by lower false positive hits and easy validation of screening hits than computational methods(Shim and Liu 2014).
**Phenotypic screening based approach**

Phenotypic screening using *in vivo* and *in vitro* cell-based assays have been central to the discovery of new drugs where chemical libraries are screened to identify ‘hits’ (Zheng et al. 2013). This method can also be used to repurpose drugs by screening a library of existing drugs to identify new activities (Reaume 2011). Extensive knowledge on mechanism of action and target is not necessary. This method is also more physiological, as intact cells and organisms are used as opposed to *in silico* methods and the chances of success for the repurposed drug to move to clinical trials is high (Zheng et al. 2013). However, the method has relatively low throughput and costly compared to *in silico* methods. Astemizole and its metabolite desmethylastemizole were identified as inhibitors of *Plasmodium falciparum* growth through this strategy (Reaume 2011).

**Literature based approach**

Novel hypotheses can be generated by linking seemingly unrelated scientific facts or indirect associations between them by analysing extensive volumes of data to identify correlations. Based on Swanson’s ABC model—two islands of knowledge A and C may be related to each other if they share a common intermediate link B (Andronis et al. 2011). The methods based on this approach include

**Chemical similarity based approach**

Similar property principle i.e., similar drugs with similar structures lead to similar biological effects, forms the base for this approach (Keiser et al. 2009). This principle is rooted in known quantitative relationships between chemical structures and biochemical activity (quantitative structural activity relationship). But, chemical structures from databases may contain errors or may be withheld as proprietary information. Some drugs undergo transformation inside the body before being active and also that physiological effects cannot be predicted on the basis of structural properties alone (Dudley et al. 2011). Mebhydrolin (Fabahistin) which binds to histamine H1 receptor was found to be chemically similar to serotonin and subsequently was found to have 5-HT5A binding affinity more than H1 receptor.

---

**Figure 3.** A) Swanson’s ABC model B) Signature similarity approach – Drug B has inverse signature similarity with the disease against which it is effective and drug A with similar signature to drug B can be potentially repurposed for the same disease C) Side effect similarity approach D) Associative indication transfer approach.
Molecular similarity/signature based approach

Administration of a pharmacologically active compound into a biological system causes perturbation of the biological system owing to the drug’s action and it is possible to construct a ‘signature’ of the molecular activity of the drug using high throughput molecular measurement techniques, such as gene expression microarrays even though the precise mechanism of action is not known. The molecular ‘signatures’ of a drug can then be compared with that of the disease to establish drug-disease relationship by anti-correlational transcriptional effects or inverse signature method (Hu and Agarwal 2009; Dudley et al. 2011; Sirota et al. 2011; Jin and Wong 2014). In a similar way, the signatures of different drugs can be compared by correlating their transcriptional effects to establish drug-drug relationship (Lamb et al. 2006; Iorio et al. 2010). The molecular activity profiles are created by exposing the drug compound to various cancer cell lines, which may not reflect the biological activity of the drug in vivo. Many drugs undergo chemical transformations when they are metabolized, and these changes are neglected in the creation of the profiles. Since many diseases affect multiple tissues and organ systems, it is difficult to represent them as single molecular activity profiles. Cimetidine, a peptic ulcer drug was repurposed for lung cancer by inverse similarity signature approach.

Connectivity map project

Connectivity map (CMap) project contains gene expression profiles for 1309 compounds by exposing these compounds to a few cancer cell lines and measuring the genome wide transcriptional response. Based on similarities in molecular activity shown in their CMap profiles, drugs can be connected to either drugs or diseases through pattern matching algorithms. If a disease is used as a query signature then drugs with inverse similarity signature can be used as treatment. In case of drug effect used as a query, the drug effect signatures stored in CMap Project similar to the query will have similar effects (Fig. 3B) (Lamb et al. 2006; Bellera et al. 2015). Dexamethasone resistance in acute lymphoblastic leukemia was overcome with concomitant use of sirolimus using the gene signature of dexamethasone resistance and sensitivity as query signatures in connectivity map profile. A high correlation was identified between the genes downregulated by sirolimus and the genes upregulated in dexamethasone resistant cells (Gns et al. 2019).

Protein structure and molecular docking – target based approach

Molecular docking involves simulation and modelling of drug-target interactions, as most small molecules exert their effect by binding to proteins or targets. A drug can be repurposed for a new disease if it is shown to interact with a protein target known to be involved in the pathogenesis of the disease. Inverse docking refers to the investigation of binding of a drug against a panel of known therapeutic targets to identify ‘off-target’ binding of the drug in question allowing for repurposing opportunities (Dudley et al. 2011; Bellera et al. 2015). However, 3-dimensional (3D) structure of ligand and protein target which are essential prerequisite for docking, are not fully resolved even for physiologically important proteins and high false-positive rates are common due to errors in protein structures (Dudley et al. 2011). Entacapone, a catechol-O-methyl transferase inhibitor used in the treatment for Parkinson’s disease is repurposed for multidrug resistant tuberculosis by identifying off-target affinity for the protein enoyl-acyl carrier protein reductase (InhA), which is involved in synthesis of the bacterial cell wall (Kinnings et al. 2009).

Genetic variation based approach

Genome-Wide Association Study (GWAS), a database developed by the National Human Genome Research Institute (NHGRI) consist of reported Single Nucleotide Polymorphisms (SNP) and their associated genetic trait expressions (Gns et al. 2019). GWAS involves sequencing of DNA of individuals and identification of common gene mutations associated with a phenotypic trait and is typically used to relate a single nucleotide polymorphism (SNP) to a disease. Diseases having different phenotype may be similar at the molecular level (share same SNPs) and by integrating drug-target interactions, a drug can be repurposed if its gene target is associated with another disease different from its original indication (Grover et al. 2014). However, gene-disease relation is more complex and, GWAS does not provide information regarding the direction of the pharmacological effect, and it is difficult to determine whether an agonist or antagonist should be used to treat the disease. Pirenzepine, a peptic ulcer drug acts on CHRM1 gene product and CHRM1 gene is a candidate gene and novel therapeutic target for Type 2 diabetes mellitus (T2DM). Pirenzepine could be potentially repurposed for T2DM (Grover et al. 2014).

Side effect similarity approach

Drugs with similar target binding profiles cause similar side-effects - this provides the basis to relate drugs to other drugs or diseases by side effect profiles, even in cases where the precise pharmacological mechanism facilitating the side effect is unknown (Fig. 3C) (Campillos et al. 2008). The disadvantages of this approach are well characterised side effect profile of drugs is not completely available for most drugs and drugs sharing a similar side effect may cause the side effect by altogether different mechanisms. Many drugs used in transplant medicine for immunosuppression have Cytomegalovirus (CMV) infection as a side effect. Based on side effect similarity approach, it can be hy-
pothesized that drugs associated with increased CMV infection risk may also be drugs for transplant rejection which may not be true always.

**Associative indication transfer approach**

'Guilt by association' – diseases are considered similar if they shared significant number of drugs. A drug can be repurposed, if it is indicated for only one disease of a pair, for the other disease of the pair (Fig. 3D)(Chiang and Butte 2009). However, applying a drug indicated for a particular disease condition, based on varied and complex drug-disease relationship, to a different disease may not prove efficacious.

**Network based method**

A network is constructed with drugs, diseases and targets as nodes and edges on the basis of connectivity established through known relationship (experimental data) or through predicted associations from data derived from cheminformatics, bioinformatics, literature-based connections and other data. In short, data from almost all methods are combined holistically, and drug repurposing is done by constructing new edges based on the topology of the network. Extensive knowledge on the drug, disease, target proteins and mode of action is necessary for construction of a network and to draw inferences from it(Yildirim et al. 2007; Liu et al. 2013; Bellera et al. 2015). The network-based approach can be divided into two types. In the network-based clustering approach, novel drug-disease/target interactions are identified by finding modules using cluster algorithms according to the networks’ topology. Vismodegib, a drug for basal cell carcinoma was predicted using the clustering method for Gorlin syndrome. In the network-based propagation strategy, prior information propagates from the source node to all network nodes and some subnetwork nodes(Xue et al. 2018).Anticonvulsant property of artificial sweeteners (saccharin, cyclamate, acesulfame) could be established through this model. They are linked with glutamate through action at T1R3 receptor which is shared by both glutamate and artificial sweeteners(Bellera et al. 2015).

**Regulatory issues**

A repurposed drug's commercial success depends on attaining effective market exclusivity through a combination of intellectual property protection and regulatory exclusivity(Smith 2011).

**Patent exclusivity**

A repurposed drug can be protected by composition of matter and/or use patent. A comparison between the modes of patent protection is shown in Table 1.

**Table 1. Comparison between composition of matter patent and method of use patent.**

| Feature | Composition of matter patent | Method of use patent |
|---------|-------------------------------|----------------------|
| Applies to | New patentable API or formulation or delivery mechanism or combination of API | New method of dosing or use for a specific indication |
| Level of protection | Strong | Weak |

*API – Active Pharmacological Ingredient.*

**Regulatory exclusivity**

This can be used for product protection in the absence of patent protection. Regulatory exclusivity differs between new chemical entities and new use/formulation (Table 2). In addition to regulatory exclusivity, we also have orphan drug exclusivity (7-year product exclusivity) and paediatric exclusivity for additional 6 months(Murteira et al. 2014). Strategic combination of new composition of matter and use patent together with a formulation and/or new use protected from generics provides strongest market exclusivity and thereby maximises the returns from the repurposed drug product(Smith 2011; Rai and Rice 2014).

**Table 2. Comparison between new chemical entity exclusivity and new use/formulation exclusivity in drugs that are being repurposed.**

| Feature | New chemical entity exclusivity | New use/formulation exclusivity |
|---------|---------------------------------|---------------------------------|
| Applies to | API not approved as marketed drug product | Addition of new indication, dose, formulation, delivery method or patient population |
| Duration | 5 years from approval | 3 years from approval |
| ANDA for generic version or 505(b)(2) new drug application for a modified version of the reference drug | Waiting period to file application | First 4 years of exclusivity period | None |
| Approval | Not before exclusivity period | Not before exclusivity period |
| Patent challenge from ANDA or 505(b)(2) to be filed along with application | After the waiting period – 4 years | None |
| Patent infringement suit from the owner of reference listed drug | Additional 30 month stay | Additional 30 month stay |

*API – Active Pharmacological Ingredient, ANDA - Abbreviated New Drug Application.

**Drug repurposing for Coronavirus disease 19 (Covid-19)**

The Covid-19 pandemic undoubtedly brought the world to a standstill but set the wheels in motion for the research community in search for a drug effective against the dreaded severe acute respiratory syndrome-coronovirus-2 (SARS-CoV2). While, conducting methodical drug trials was fraught with logistic and scientific challenges and with no vaccine in sight in the near future during the initial phase of the raging pandemic, drug repurposing offered probably the only hope of finding 'hits' potentially useful against Covid-19(Sultana et al. 2020). The drugs initially chosen to repurpose against Covid-19 were those which have shown in vitro efficacy or those that were used prior for severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS)(Martinez 2021). However, with the computational
repurposing approaches hundreds of drug candidates have been repurposed thanks to the resolution of 3D structure of viral proteins and viral genomic sequencing. As of October 2020, about 500 structures of the viral proteins with or without their associated ligands or target receptors have been made public to the research community which triggered off the explosion of repurposable hits. The major computational strategies employed for repurposing against Covid-19 included network-based approach, structure-based approach, and artificial intelligence-based approach. Molecular docking based on 3D viral structure augmented by molecular dynamic simulations and other methods are the main structure-based approach for repurposing. Drug repurposing strategies for Covid-19 based on artificial intelligence algorithms are few. Among the various methods, majority of the drugs were repurposed based on molecular docking method (Dotolo et al. 2020). The in silico approach facilitated drugs such as amiodarone, bromhexine and others being tested against the virus. The repurposed drugs with their potential targets and proposed mechanism(s) of action are tabulated in Table 3 (Parvathaneni and Gupta 2020; Senanayake 2020; Singh et al. 2020; Sultana et al. 2020; Kifle et al. 2021; Taneja 2021). A detailed discussion on the individual drugs is outside the scope of this review. Drug repurposing made possible for drugs getting approved under accelerated regulatory process by the major drug approval agencies across the globe.

### Table 3. Drugs repurposed for Covid-19.

| Therapeutic Effect | Drug | Proposed mechanism of action |
|--------------------|------|-----------------------------|
| Viral entry blockers | Ibrutinib | Inhibit BCR Kinase |
| Viral entry inhibitors | Abivertinib | Inhibit EGFR kinase |
| Viral entry inhibitors | Ruxolitinib | Inhibit JAK 1/2 |
| Viral entry inhibitors | Baricitinib | Inhibit JAK 1/2 |
| Viral entry inhibitors | Infliximab | Inhibit TNF-α |
| Viral entry inhibitors | Ravulizumab | Inhibit C5 |
| Viral entry inhibitors | Canakinumab | Inhibit IL-1β |
| Viral entry inhibitors | Olokizumab | Inhibit IL-6 |
| Viral entry inhibitors | Clazakizumab | Inhibit IL-6 |
| Viral entry inhibitors | Sarilumab | Inhibit IL-6 |
| Viral entry inhibitors | Tocilizumab | Inhibit IL-6 |
| Viral entry inhibitors | Doxycycline | Reduces cytokine production |
| Miscellaneous | Prednisolone | Anti-inflammatory |
| Miscellaneous | Methyl prednisolone/ Dexamethasone | Anti-inflammatory |
| Miscellaneous | Atorvastatin | Lipid lowering |
| Miscellaneous | Selinexor | HDAC inhibitor |
| Miscellaneous | Oseltamivir | Inhibit neuraminidase |
| Miscellaneous | Sofosbuvir | RNA polymerase inhibitor |
| Miscellaneous | Cepharanthine | Anti-inflammatory |
| Miscellaneous | Danoprevir | HCV NS3/4A protease inhibitor |
| Miscellaneous | Lopinavir-ritonavir | HIV protease inhibitor |
| Miscellaneous | Emtricitabine | Reverse transcriptase inhibitor |
| Miscellaneous | Ribavirin | FDA approved for HCV |
| Miscellaneous | Clevudine | FDA approved for HCV |
| Miscellaneous | Tenofovir alafenamide | FDA approved for HCV |
| Miscellaneous | Galidesivir | FDA approved for HCV |
| Miscellaneous | Favipiravir | FDA approved for HCV |
| Miscellaneous | Bictegravir | FDA approved for HIV |
| Miscellaneous | Arbidol | FDA approved for influenza |
| Miscellaneous | Imatinib | FDA approved for CML |
| Miscellaneous | Chlorpromazine | FDA approved for schizophrenia |
| Miscellaneous | Amiodarone | FDA approved for atrial fibrillation |
| Miscellaneous | Droxychloroquine | FDA approved for malaria |
| Miscellaneous | Chloroquine/hydroxychloroquine | FDA approved for malaria |
| Miscellaneous | Nelfinavir | FDA approved for HIV |
| Miscellaneous | Umifenovir | FDA approved for influenza |
| Miscellaneous | Camostat mesilate | FDA approved for hemorrhage |
| Miscellaneous | Bicalutamide | FDA approved for prostate cancer |
| Miscellaneous | Acid | FDA approved for acne |
| Miscellaneous | Isotretinoin/retinoic acid | FDA approved for acne |
| Miscellaneous | Spironolactone | FDA approved for hypertension |
| Miscellaneous | Estradiol | FDA approved for osteoporosis |

*ACE - Angiotensin Converting Enzyme, ARB - Angiotensin receptor 1 blocker, ARDS – Acute Respiratory Distress Syndrome, AP2 – Adaptor protein 2, CCR5 – C-C chemokine Receptor type 5, DNA – DeoxyriboNucleic Acid, DPP4 – Dipeptidyl Peptidase 4, ECoV – Epidermidal Growth Factor Receptor, GM-CSF –Granulocyte-Macrophage-Colony Stimulating Factor, GTP – Guanosine Tri Phosphate, IFNγ – Interferon Gamma, TMPRSS2 - TransMembrane Serine Protease-2, TNFa – Tumor Necrosis Factor alpha, VEGF – Vascular Endothelial Growth Factor, VIP – Vasoactive Intestinal Peptide.*
Limitations of drug repurposing

Drugs repurposed for reasons in addition to novel indication such as new dosage, new formulation or new patient population have to undergo clinical trials to demonstrate safety and efficacy which is almost similar to de novo drug discovery process. Even for drugs entering late phase clinical trials, the cost involved in bringing the drug to market is still in millions and the drug can still fail during clinical trials or post-marketing, though the failure rate is low compared to new drug discovery (Naylör and Schönfeld 2014). In-silico methods suffer from incomplete knowledge about complex biological systems (Thayer 2012). Drugs that could potentially be repurposed are growing in number due to upsurge in the academic enthusiasm in drug repurposing which lowers the credibility of in-silico methods, since most of these drugs are unlikely to pass validation and proceed through clinical trials to regulatory approval and making to the market (Oprea and Mestres 2012).

Selected examples

Selected drugs which had a big bang, thanks to drug repurposing are cited in Table 4.

Table 4. Top mini-blockbuster and blockbuster repurposed drugs.

| Drug                | Original indication                  | New indication (year) |
|---------------------|-------------------------------------|-----------------------|
| Gemcitabine         | Anti-viral                           | Various Cancers (Various) |
| Raloxifene          | Osteoporosis                         | Invasive Breast Cancer (2007) |
| Finasteride         | Hypertension                         | Benign prostatic hyperplasia (1992) |
| Thalidomide         | Anti-Nausea                          | Erythema Nodosum Leprosum (1998) |
| Sildenafil          | Angina                              | Erectile Dysfunction (1998) |
| Rituximab           | Various Cancers                     | Pulmonary Dysfunction (2005) |
| Dimethyl fumarate   | Psoriasis                           | Rheumatoid Arthritis (2004) |

Failed repurposed drugs

Though repurposing appears to be an attractive strategy, several challenges exist for the drugs identified to be repurposed before making it to the market. These include, but not limited to, low potency, dose adjustments, new safety signals and route of administration (Parvathaneni and Gupta 2020). Data available from in vitro and animal studies may not be generalisable to humans. With regard to computational approaches such as molecular docking, because of the diversity of the protein database and differences in the algorithm used for docking, there is differing agreements on drugs converging on same targets (Dotolo et al. 2020). There is an estimated 65% attrition rate for repurposed drugs (DCAT value insights 2021). Chloroquine/hydroxychloroquine touted to be the game changer in the battle against Covid-19 fizzled out in a matter of few months. The Food and Drug Administration (FDA) agency revoked emergency use authorisation (EUA) granted to these antimalarials for lack of efficacy and cardiac adverse events within 3 months of initial approval (Parvathaneni and Gupta 2020). Remdesivir, a drug initially developed for hepatitis C, was repurposed against Ebola virus but failed to show efficacy and later found to be effective against MERS in animal studies also received EUA for Covid-19 (Borowiec 2020; Parvathaneni and Gupta 2020). However, the interim results of WHO Solidarity trial failed to show benefits in terms of mortality, ventilation initiation and hospital stay in Covid-19 hospitalised patients with remdesivir. Hydroxychloroquine, lopinavir and interferon regimens were also found to be ineffective in this large randomised controlled trial (RCT) of more than 11000 patients (WHO solidarity trial consortium 2020). Another large RCT, the Randomised Evaluation of COVid-19 thErapY (RECOVERY) Trial of over 20000 hospitalised Covid-19 patients demonstrated the lack of efficacy for azithromycin, aspirin, colchicine, hydroxychloroquine, and lopinavir-ritonavir against the virus (RECOVERY Collaborative group 2020a, 2020b, 2021; Iacobucci 2021; RECOVERY collaborative group 2021). With the failure of initially promising drugs, current repurposing research is focussing on multiple targets of the viral structure such as spike protein and main protease or virus-host targets such as spike protein-angiotensin converting enzyme-2 (ACE2) receptor interface and main protease, or transmembrane serine protease-2 (TMPRSS2) and main protease using drug combinations (Dotolo et al. 2020; Martínez 2021).

Bupropion, a norepinephrine and dopamine reuptake inhibitor in combination with naltrexone, a pure opioid antagonist was approved as an adjunct for weight management in adults by FDA in December 2010 (Plodkowski et al. 2009; The San Diego Union-Tribune 2014). Within 3 months of approval, FDA rejected the drug for need of studies on cardiovascular safety of the drug. However, FDA approved the combination for marketing in September 2014 with studies pending on safety. The product labelling contains a boxed warning regarding suicidal intentions and a note that cardiovascular safety has not been established as a limitation of use (Center for Drug Evaluation and Research 2019).

Bevacizumab, a humanised anti-VEGF monoclonal IgG1 antibody has been approved for treatment of advanced colorectal carcinoma, advanced non-small cell lung carcinoma, metastatic breast carcinoma and advanced renal cell carcinoma in addition to chemotherapy (Kazazi-Hyseni et al. 2010). The drug failed to meet the primary end point of improvement in overall survival of advanced gastric carcinoma patients in addition to capetibine and cisplatin in a phase III trial despite having a preclinical and phase II study evidence (Kang et al. 2010).

Conclusion

Drug repurposing – a second life for failed drugs and drug candidates, and expanding successful ones, appears to offer some real solution to the problem the pharma-
ceutical industry is facing by turning the tables on pipeline erosion and also offers the prospect of identifying treatment for unmet medical needs, finding safer, efficacious and cheaper drugs to the community. Drug repurposing strategies have their own pros and cons and selection of a combination of strategies tailored to the need is essential for a repurposed drug to make it to the market and be successful.

“Although a bit of an exaggeration, there is a lot of truth in the saying that we do not need to find new drugs; rather we need to find the patients who can benefit from existing drugs” - Christopher Lipinski.

References:

Andronis C, Sharma A, Virvilis V, Deftereos S, Persidis A (2011) Literature mining, ontologies and information visualization for drug repurposing. Briefings in Bioinformatics 12: 357–368. https://doi.org/10.1093/bib/bbr005

Baker NC, Ekins S, Williams AI, Tropsa A (2018) A bibliometric review of drug repurposing. Drug discovery today 23: 661–672. https://doi.org/10.1016/j.drudis.2018.01.018

Bellera CL, Di Ianni ME, Sbaraglini ML, Castro EA, Bruno-Blanch LE, Talevi A (2015) Chapter 2 - Knowledge-Based Drug Repurposing: A Rational Approach Towards the Identification of Novel Medical Applications of Known Drugs. In: UI-Haq Z, Madura JD (Eds) Frontiers in Computational Chemistry. Bentham Science Publishers, 44–81. https://doi.org/10.1016/B978-1-60805-865-5.50002-2

Borowiec BG (2020) Drug repurposing gave remdesivir its second, third, and fourth chance. Massive science. https://massivesci.com/articles/remdesivir-coronavirus-covid19-ebola-repurposing-vaccine/ [September 27, 2021]

Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science (New York, N.Y.) 321: 263–266. https://doi.org/10.1126/science.1158140

Center for Drug Evaluation and Research (2019) Orexigen Therapeutics, Inc. (Contrave) Untitled Letter 5/18/2017. https://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/orexigen-therapeutics-inc-contrave-untitled-letter-5182017 [October 10, 2021]

Chen H, Zhang H, Zhang Z, Cao Y, Tang W (2015) Network-Based Inference Methods for Drug Repositioning. Computational and Mathematical Methods in Medicine 2015: 1–7. https://doi.org/10.1155/2015/130620

Chiang AP, Butte AJ (2009) Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clinical Pharmacology and Therapeutics 86: 507–510. https://doi.org/10.1038/clpt.2009.103

DCAT [Drug, Chemical & Associated Technologies association] value chain insights (2021): Feeling Pressure ‘To Shorten Early Development Timelines’ https://www.dcatvci.org/feeling-pressure-to-shorten-early-development-timelines. [September 27, 2021]

Dotolo S, Marabotti A, Facchiano A, Tagliaferri R (2020) A review on drug repurposing applicable to COVID-19. Briefings in Bioinformatics. bba2288. https://doi.org/10.1093/bib/bba2288

Dudley JT, Deshpande T, Butte AJ (2011) Exploiting drug-disease relationships for computational drug repositioning. Briefings in Bioinformatics 12: 303–311. https://doi.org/10.1093/bib/bbr013

Gns HS, Gr S, Murahari M, Krishnamurthy M (2019) An update on Drug Repurposing: Re-written saga of the drug’s fate. Biomedicine & Pharmacotherapy 110: 700–716. https://doi.org/10.1016/j.biopha.2018.11.127

Grover MP, Ballouz S, Mohanasundaram KA, George RA, H Sherman CD, Crowley TM, Wouters MA (2014) Identification of novel therapeutics for complex diseases from genome-wide association data. BMC Medical Genomics 7: S8. https://doi.org/10.1186/1755-8794-7-S1-S8

Hu G, Agarwal P (2009) Human Disease-Drug Network Based on Genomic Expression Profiles. PLoS ONE 4: e6536. https://doi.org/10.1371/journal.pone.0006536

Iacobucci G (2021) Covid-19: Aspirin does not improve survival for patients admitted to hospital, trial reports. BMJ (Clinical research ed.) 373: n1475. https://doi.org/10.1136/bmj.n1475

Iorio F, Bosotti R, Scachetti E, Belcastro V, Mithbaokar P, Ferriero R, Munico L, Tagliaferri R, Bruinetti-Pierri N, Isacchi A, di Bernardo D (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proceedings of the National Academy of Sciences 107: 14621–14626. https://doi.org/10.1073/pnas.1000138107

Jin G, Wong STC (2014) Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discovery Today 19: 637–644. https://doi.org/10.1016/j.drudis.2013.11.005

Jin G, Fu C, Zhao H, Cui K, Chang J, Wong STC (2012) A Novel Method of Transcriptional Response Analysis to Facilitate Drug Repositioning for Cancer Therapy. Cancer Research 72: 33–44. https://doi.org/10.1158/0008-5472.CAN-11-3333

Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park S, Lim H, Wu J, Langer B, Shah MA (2010) AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capcitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). Journal of Clinical Oncology 28: LBA4007–LBA4007. https://doi.org/10.1200/jco.2010.28.18_suppl.Lba4007

Kazazi-Hyseni F, Beijnen JH, Schellens JHM (2010) Bevacizumab. The Oncologist 15: 819–825. https://doi.org/10.1634/theoncologist.2009-0317

Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RG, Tran TB, Whealy R, Glennon RA, Hert J, Thomas KLH, Edwards DD, Shoichet BK, Roth BL (2009) Predicting new molecular targets for known drugs. Nature 462: 175–181. https://doi.org/10.1038/nature08506

Kifle ZD, Ayele AG, Enyew EF (2021) Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. Journal of Environmental and Public Health 2021: e6631721. https://doi.org/10.1155/2021/6631721

Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE (2009) Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Computational Biology 5: e1000423. https://doi.org/10.1371/journal.pcbi.1000423

Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN, Reich M, Hirschmanus H, G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (New York, N.Y.) 313: 1929–1935. https://doi.org/10.1126/science.1132939
Lekka E, Deftereos SN, Persidis A, Persidis A, Andronis C (2011) Literature analysis for systematic drug repurposing: a case study from Biovista. Drug Discovery Today: Therapeutic Strategies 8: 103–108. https://doi.org/10.1016/j.drudis.2011.06.005
Liu Z, Fang H, Reagan K, Xu X, Mandrick DL, Slikker W, Tong W (2013) In silico drug repositioning – what we need to know. Drug Discovery Today 18: 110–115. https://doi.org/10.1016/j.drudis.2012.08.005
Martinez MA (2021) Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment. Frontiers in Immunology 12: e653. https://doi.org/10.3389/fimmu.2021.635371
Mucke H (2010) Drug Repositioning: Extracting Added Value from Prior R&D Investments.
Murteira S, Millier A, Ghezaïd Z, Lamure M (2014) Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications. Journal of Market Access & Health Policy 2. https://doi.org/10.3402/jmahp.v2.22813
Naylor S, Schönfeld JM (2014) Therapeutic drug repurposing, repositioning and rescue - Part I: Overview. Drug Discovery World 16: 49–62.
Oprea T
M, Mestres J (2012) Drug Repurposing: Far Beyond New Targets for Old Drugs. The AAPS Journal 14: 759–763. https://doi.org/10.1208/s12248-012-9390-1
Parvathaneni V, Gupta V (2020) Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges. Life Sciences 259: e118275. https://doi.org/10.1016/j.lfs.2020.118275
Pihan E, Colliandre L, Guichou J-F, Douguet D (2012) e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. Bioinformatics 28: 1540–1541. https://doi.org/10.1093/bioinformatics/bts186
Plodkowski RA, Nguyen Q, Sundaram Z, Lamure M, St Jeor S (2009) Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opinion on Pharmacotherapy 10: 1069–1081. https://doi.org/10.1517/14656569.09.2775750
R Flower D (2013) Pharmacovigilance, Drug Repositioning, and Virtual Screening. Journal of Pharmacovigilance 01. https://doi.org/10.4172/2329-6887.1000e103
Rai AK, Rice G (2014) Use Patents Can Be Useful: The Case of Rescued Drug Indications through Automated Reasoning. Ahmad A (Ed.). PLoS ONE 7: e40946. https://doi.org/10.1371/journal.pone.0040946
Thayer AM (2012) Drug Repurposing. Chemical & Engineering News 90. https://doi.org/10.1021/ecn-90040-cover [July 22, 2021]
The San Diego Union-Tribune (2014) FDA OKs Orexigen’s weight loss pill. https://www.sandiegouniontribune.com/business/biotech/sdut-orexigen-contrave-fda-approved-2014sep10-story.html [October 10, 2021]
WHO solidarity trial consortium (2020) Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. The New England Journal of Medicine: NEJMoa2023184. https://doi.org/10.1056/NEJMoa2023184
Xue H, Li J, Xie H, Wang Y (2018) Review of Drug Repositioning Approaches and Resources. International Journal of Biological Sciences 14: 1232–1244. https://doi.org/10.7150/ijbss.24612
Yildirim MA, Koh-K, Cusick ME, Barabási A-L, Vidal M (2007) Drug-target network. Nature Biotechnology 25: 1119–1126. https://doi.org/10.1038/nbt1338
Zheng W, Thorne N, McKew JC (2013) Phenotypic screening as a renewed approach for drug discovery. Drug Discovery Today 18: 1067–1073. https://doi.org/10.1016/j.drudis.2013.07.001